{"id":"NCT00561574","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)","officialTitle":"A Randomized Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of Org 50081","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01-09","primaryCompletion":"2010-02-14","completion":"2010-02-14","firstPosted":"2007-11-21","resultsPosted":"2014-07-07","lastUpdate":"2021-01-27"},"enrollment":259,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sleep Initiation and Maintenance Disorder; Elderly","Mental Disorder","Dyssomnias","Sleep Disorders","Sleep Disorder, Intrinsic"],"interventions":[{"type":"DRUG","name":"Esmirtazapine","otherNames":[]}],"arms":[{"label":"Esmirtazapine 1.5 mg","type":"EXPERIMENTAL"},{"label":"Esmirtazapine 3.0 mg","type":"EXPERIMENTAL"}],"summary":"The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and tolerability of long-term treatment with esmirtazapine in elderly patients.","primaryOutcome":{"measure":"Number of Participants Who Experience at Least One Adverse Event (AE)","timeFrame":"Up to 53 weeks","effectByArm":[{"arm":"Esmirtazapine 1.5 mg","deltaMin":115,"sd":null},{"arm":"Esmirtazapine 3.0 mg","deltaMin":116,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":23},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":128},"commonTop":["Nasopharyngitis","Fatigue","Weight increased","Dizziness","Headache"]}}